



## Detailed Investigation of Downstream TLR Signaling in the Follicular Cells of Women with Endometriosis

Reza Jafari<sup>1</sup>, Seyed Abdolvahab Taghavi<sup>2</sup>, Elham Amirchaghmaghi<sup>3</sup>, Reza Salman Yazdi<sup>4</sup>, Leili Karimian<sup>5</sup>, Mahnaz Ashrafi<sup>3,6</sup>, Reza Aflatoonian<sup>3\*</sup>

1- School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran

2- Department of Gynecology and Obstetrics, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran

3- Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

4- Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

5- Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

6- Department of Gynecology and Obstetrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

### Abstract

**Background:** Inflammatory responses within the peritoneal cavity may result in endometrial dysfunction in women with endometriosis. The true causes of this disease remain poorly understood. It is hypothesized that downstream toll-like receptors (TLRs) inflammatory cytokines in response to pathogens may be associated with endometriosis. So, this study was aimed at evaluating the expression of TLRs signaling and endometriosis-associated inflammatory responses.

**Methods:** Totally, 20 infertile endometriosis patients and 20 normal women undergoing controlled ovarian stimulation were enrolled. The cellular pellet and supernatant were obtained by centrifugation of follicular fluid (FF). Evaluation of TLRs and their signaling pathway gene expression was performed on cellular pellets using quantitative-PCR. The supernatant was used for determination of cytokine protein expression by ELISA. The results are expressed as mean±SEM and a  $p < 0.05$  was considered statistically significant.

**Results:** Quantitative-PCR analysis suggested that TLR1, 5, 6, 7, 8, 10, MYD88, NF- $\kappa$ B, IL-10 and TGF- $\beta$  genes expression significantly increased in patients compared to the control group ( $p < 0.05$ ). TLR3, 9, INF- $\beta$  genes expression was significantly lower in endometriosis than control group ( $p < 0.05$ ). There was no significant difference in the expression of TLR2, TLR4, TIRAP, TRIF, TRAM, and IRF3 between two groups. Also, significant increase in the levels of IL-6, IL-8 and MIF protein in FF of endometriosis group was detected in comparison with normal women ( $p < 0.05$ ).

**Conclusion:** The expression of TLR downstream signaling in the follicular cells can initiate inflammatory responses and changes in the FF cytokine profile which in turn may induce endometriosis and infertility disorder.

**Keywords:** Endometriosis, Follicular cells, Infertility, Inflammation, TLR.

**To cite this article:** Jafari R, Taghavi SA, Amirchaghmaghi E, Yazdi RS, Karimian L, Ashrafi M, et al. Detailed Investigation of Downstream TLR Signaling in the Follicular Cells of Women with Endometriosis. *J Reprod Infertil*. 2020;21(4):231-239. <http://dx.doi.org/10.18502/jri.v21i4.4325>.

\* Corresponding Author:  
Reza Aflatoonian, Royan  
Institute, Number 12, East  
Hafez Avenue, Bani  
Hashem Street, Resalat  
Highway, Tehran, Iran,  
Postal codes: 148-16635  
E-mail:  
[r.aflatoonian@gmail.com](mailto:r.aflatoonian@gmail.com)

Received: Sept. 8, 2019

Accepted: Apr. 4, 2020

### Introduction

Endometriosis is a usual gynecologic disorder associated with infertility that affects reproductive-aged women (1). Endometriosis is an

enigmatic condition in which endometrial glands or stromal cells grow in the extra-uterine locations such as fallopian tubes (2). There is no unifying

theory that adequately explains the etiology and pathophysiology of endometriosis (3). However, genetic susceptibilities, hormonal or immunologic factors may be involved in the pathogenesis of the disease (4). In the last few decades, many more studies have illustrated the role of immune responses in the etiology and pathophysiology of endometriosis (5-7). Normally, the immune system can clear refluxed endometrial tissues. Therefore, the predisposition to implantation and growth of endometrial cells could be due to dysregulation of immune clearance mechanism (4).

Many studies have reported that engagement of toll-like receptors (TLRs) by gram-positive and gram-negative bacterias in the vaginal route can initiate inflammatory responses which leads to the promotion of infectious diseases such as endometritis (8, 9). TLRs play essential roles in the innate immune system by recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (10). The expression of TLRs in the human female reproductive system has been established (11). By now, ten members of TLR family have been identified in human which are expressed on various immune and non-immune cells (12-14). TLR1, 2, 4, 5, 6 and TLR10 are expressed on the cell surface where as TLR3, 7, 8 and TLR9 are located in cellular endosome (10, 15). There are published studies that have reported TLRs 1–10 are expressed in the female reproductive tract (2, 16) and their expression level varies in different phases of menstrual cycles (17). *In vitro* studies have shown that ligation of TLRs on endometrial epithelial cell lines triggers the production of inflammatory cytokines including interleukin 6 (IL-6) and IL-8 (18). The expression of TLRs 2, 4, 8 and 9 in mouse granulosa and cumulus cells has also been reported (19). TLRs-ligand interaction activates downstream signaling pathways including adaptor molecules MYD88, nuclear factor kappa B (NF- $\kappa$ B) and interferon regulatory factor (IRF) 3 and 7 that enhance secretion of pro-inflammatory cytokines and chemokines such as interleukins 6, 8, 10 and macrophage migration inhibitory factor (MIF) (20). It was reported that the peritoneal fluid of women with endometriosis contained significantly elevated levels of the chemokines, monocyte chemoattractant protein-1 (MCP-1) and IL-8 (21). On the other hand, the proliferation of human endometrial stromal cells may be inhibited by interleukin-6 (22). Also, the severity of endometriosis is correlated with levels of IL-6 in peritoneal fluid

(23). However, there is no strong evidence to support it and more detailed studies are needed to clarify all aspects of dysregulation of the immune system in the development and progress of endometriosis. The aim of the present study was investigation of changes in TLRs and their signaling pathway gene expression in the follicular cells of infertile women with endometriosis.

## Methods

**Study design:** This case-control study was approved by Ethics Committees of Royan Institute. Forty patients (20 infertile endometriosis patients and 20 normal women with male factor infertility as a control) who attended Reproductive Medicine Unit in the Royan Infertility Clinic, Tehran, Iran, for intracytoplasmic sperm injection (ICSI) treatment were the subjects of the study. An information sheet was offered to all women and informed written consent was obtained. The infertile women aged 20-35 undergoing ICSI treatment with the same standard long protocol and patients with stage III endometriosis in laparoscopic assessment were selected. Stage III endometriosis was defined as the presence of endometriomas on the ovary (24). Patients with hyper-prolactinemia, poor ovarian response and history of ovarian surgery and infection were excluded. The anthropometric measurements were accomplished, based on body mass index [BMI, calculated as  $\text{weight}/(\text{height})^2$  ( $\text{kg}/\text{m}^2$ )]. The hormones such as LH, FSH, testosterone were also determined. All laboratory parameters were checked in the early follicular phase of the menstrual cycle.

**Protocol for controlled ovarian stimulation:** In this study, to minimize bias, all women were administered a standard long protocol using GnRH-agonist (Superfact, Aventis, Germany). GnRH-a started around day 17-19 of the natural menstrual cycle as a pre-treatment. A daily dose of 0.5 mg was used subcutaneously when pituitary desensitization was confirmed (Endometrial thickness  $<5$  mm and serum estradiol level  $<50$  pg/ml), then the GnRH-a dose was reduced by one-half and ovarian stimulation was initiated. The ovarian stimulation started with a dose of 150-225 IU r-FSH (Gonal-F, Merck Serono, Switzerland) concerning the patient's age and was continued until the day of ovulatory human chorionic gonadotropin (hCG) administration according to the ovarian response. When at least two follicles were greater than 18 mm, 10,000 IU urinary hCG (Choriomon, IBSA, Switzerland) was administered intramuscularly for

ovulation induction and oocyte retrieval was performed 34-36 hr later (25).

**Sample collection:** FF aspiration was carried out with transvaginal ultrasound guidance aspirating the largest follicles (>18 mm) without flashing and blood contamination. The follicular fluid (FF) was transferred to a sterile Petri dish, then the oocytes were removed. The fluid was collected into a 15-ml conical tube and centrifuged at 300 g for 5 min.

**RNA isolation, cDNA synthesis and RT-PCR:** The supernatant was removed and 1ml of TRI reagent (Sigma, Pool, UK) was added to the cell pellet and homogenized for total RNA extraction following a standard protocol according to manufacturer's instruction. Obtained total RNA, in both groups, was treated three times with DNase I (Fermentase, Germany) to remove genomic DNA contamination from the samples. The first-strand cDNA synthesis was performed using oligo (dT) primers and reverse transcription was done by SuperScript II (Fermentase). Negative controls were prepared without the addition of the enzyme (Non-reverse transcribed controls, RT controls). The RT-PCR was performed using the cDNA of each sample. Briefly, the amplification was persistent for 40 cycles under the following setting: 95 °C for 30 s, 60-63 °C (Table 1) for 30 s, and

72 °C for 30 s. B-actin and GAPDH were used as internal controls and their expressions were checked between two groups.

**Quantitative real-time PCR (QPCR):** The Q-PCR was performed for evaluating myeloid differentiation primary response protein (MYD88), TIR domain containing adaptor protein (TIRAP), TIR-domain-containing adapter-inducing interferon- $\beta$  (TRIF), TRIF-related adaptor molecule (TRAM), NF- $\kappa$ B, interferon regulatory factor 3 (IRF3), interferon- $\beta$  (INF- $\beta$ ), IL-10 and transforming growth factor beta (TGF- $\beta$ ) with the CDNA prepared from the follicular cells pallet. The forward and reverse primers for each gene were designed by Primer-BLAST (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) (Table 1). The qPCR reactions were carried out in triplicates using an ABI Prism 7300 Sequence Detector (Applied Biosystems, Foster, USA) in a total volume of 20  $\mu$ l containing 250 ng of cDNA, 5 pmol of gene specific primers and SYBR green reagent (Applied Biosystems) with ROX dye as a passive control for signal intensity. The thermal cycle profile included 50 cycles at 95 °C for 30 s, 60-63 °C (Table 1) for 30 s, and 72 °C for 30 s (26). Samples were run in triplicate. Melting curve analysis was used for the determination of the specificity of the PCR fragments. All

Table 1. List of primers

Gene	Forward primer (5-3)	Reverse primer (3-5)	Annealing temperature (°C)	Product size (bp)
TLR1	GGGTCAGCTGGACTTCAGA	AAAATCCAAATGCAGGAACG	63	250
TLR2	TCGGAGTTCTCCCAGTTCTCT	TCCAGTGCTTCAACCCACAA	60	175
TLR3	GTATTGCCTGGTTTGTAAATTGG	AAGAGTTCAAAGGGGGCACT	60	156
TLR4	TGATGTCTGCCTCGCGCCTG	AACCACCTCCACGCAGGGCT	60	98
TLR5	CACCAAACAGGGATGCTAT	CCTGTGTATTGATGGGCAAA	60	111
TLR6	GCCACCATGCTGGTGTGGCT	CGCCGAGTCTGGGTCCACTG	60	101
TLR7	CCTTGAGGCCAACAACATCT	GTAGGGACGGCTGTGACATT	63	285
TLR8	CTTCGATACCTAAACCTCTCTAGCAC	AAGATCCAGCACCTTCAGATGA	60	90
TLR9	TTCCCTGTAGCTGCTGTCC	ACAGCCAGTTGCAGTTCACC	60	207
TLR10	TGCCCACCACAATCTCTTCCATGA	AGCAGCTCGAAGGTTTGCCCA	60	184
MYD 88	GTCTCCTCCACATCCTCCCT	TCCGCACGTTCAAGAACAGA	60	82
TIRAP	CCTGCTGAAGAAGCCCAAGA	GGTTGTCCTGTGAGGTAGGC	60	83
TRIF	GAAGGAACAGGACACCCGAG	TGAGTAGGCTGCGTTCAGTG	60	91
TRAM	TGAAGCCCTCAGAGTCCAGA	TCTGCCACATGGCATCTCAG	60	85
NF- $\kappa$ B	CTGGATCTGCTGGTGGACAG	CTGTGGCTAGATGCAAGGCT	60	82
IRF 3	CTTGGTGGAGGGCATGGATT	GTTGAGGTGGTGGGGAACAG	60	96
IFN- $\beta$	ACGCCGATTGACCATCTAT	GTCTCATTCCAGCCAGTGCT	60	85
IL-10	AAGACCCAGACATCAAGGCG	AGGCATTCTTCACCTGCTCC	60	135
TGF- $\beta$	GGAGCAGCTGTCCAACATGA	GGGCACGGGTGTCCTTAAAT	60	146
B-Actin	CAAGATCATTGCTCCTCCTG	ATCCACATCTGCTGGAAGG	60	90
GAPDH	CTCATTTCTGGTATGACAACGA	CTTCCTCTGTGCTCTTGCT	60	122

melting curves produced one peak per PCR product. Standard curves were obtained using the logarithmic dilution series of total RNA. The efficiency of the RT-PCR was 98%. The qPCR data were analyzed using the comparative CT method (27) and fold change was calculated as  $FC=2^{-\Delta\Delta CT}$ .

**Immunoassay:** The follicular fluid from each patient was centrifuged at 300 *g* for 5 *min*, then the supernatant was used to measure the concentration of IL-6, IL-8, and MIF by commercially enzyme-linked immunosorbent assay (ELISA) kits. Briefly, this technique uses a microwell plate coated with a monoclonal antibody specific for human IL-6 (eBioscience, minimal detection level <1 *pg/ml*), human IL-8/NAP-1 (eBioscience, minimal detection level <5 *pg/ml*), and human MIF (Glory Science, minimal detection=3 *mg/ml*). The preparation was added to each well and incubated at room temperature for 1 *hr*. Then, plates were washed three times using phosphate-buffered saline (PBS). The biotin-conjugated anti-human IL-6, IL-8, and MIF monoclonal antibody was added to each plate. The plates were washed again and streptavidin-HRP and tetramethyl-benzidine as a substrate was added to each well. Optical density (OD) was measured by ELISA reader at 450 *nm*. The concentration of each cytokine was determined by comparing the optical density of samples.

**Statistics:** The results were expressed as mean±SEM. Statistical analysis was performed by using a t-test using SPSS 22 software. The *p*<0.05 was

**Table 2.** Demographic and clinical characteristics of patients

Variable	Endometriosis (n=20)	Control (n=20)	P
Age (Years)	29.78±4.52	30.75±3.89	0.48
BMI ( <i>kg/m</i> <sup>2</sup> )	24.75±3.19	25.20±4.19	0.70
LH ( <i>mU/ml</i> )	3.41±1.65	5.02±3.39	0.07
FSH ( <i>mU/ml</i> )	6.86±2.80	8.55±5.73	0.23
LH/FSH ratio	0.55±0.30	0.64±0.33	0.40
Testosterone ( <i>ng/ml</i> )	1.35±0.44	1.31±0.54	0.87
No. of mature oocytes	5.35±4.5	10.1±1.59	<0.001

Presented as mean±SD and compared by t-test  
BMI: Body Mass Index


considered significant. For real-time data,  $2^{-\Delta\Delta CT}$  was calculated for each gene, then the data was analyzed using the GraphPad PISM 8 software.

**Ethical consideration:** All procedures were approved by the Ethics Committee of Royan Institute and informed consent was obtained from each patient before the sample collection.

## Results

The demographic and clinical characteristics of patients are presented in table 2. The number of mature oocyte is significantly lower in endometriosis samples compared to the control group. There is no significant difference in other items between the two groups.

The quantitative expression profiles of TLR1–10 genes in follicular cells in both groups are shown in figure 1. TLR1, 5, 6, 7, 8 and TLR10 showed a



**Figure 1.** QPCR was used to quantify the expression of TLRs mRNA in endometriosis and control groups. Data are presented as mean±SEM of normalized expression values against endogenous controls (B-actin and GAPDH mRNA) in endometriosis and control group. TLR1, 5, 6, 7, 8 and TLR10 showed a significantly higher expression in endometriosis patients compared with the normal women. TLR2 and TLR4 showed no significant difference in both groups. TLR3, 9 showed significantly lower expressions in endometriosis patients compared with the control. Data were analyzed by t-test. The level of significance was set at *p*<0.05.

**Table 3.** The fold change and p-value of each gene

Gene	Fold change	p-value (<0.05)
TLR1	5.142	0.0009
TLR2	1.13	0.2711
TLR3	12.16	0.0001
TLR4	1.96	0.5239
TLR5	3.23	0.021
TLR6	5.95	0.0011
TLR7	7.07	0.0003
TLR8	8.33	0.0003
TLR9	12.931	<0.0001
TLR10	11.89	0.00001
MYD88	10.03	0.0028
TRIF	1.34	0.6701
TRAM	2.07	0.2839
TRAP	0.94	0.6086
NF-κB	13.80	0.0055
IRF3	1.78	0.5741
INF-β	6.02	0.0012
IL-10	5.12	0.0052
TGF-β	9.77	0.0021
IL-6	14.75	<0.00001
IL-8	20.14	<0.00001
MIF	18.98	<0.00001

significantly higher expression in endometriosis patients compared to the control ( $p<0.05$ ). The fold change and exact p-value of each gene are shown in table 3. There was no significant difference in the expression of TLR2 and 4 in both groups. TLR3, 9 showed significantly lower expressions in endometriosis patients compared with the control ( $p<0.05$ ). The quantitative expression profile of MYD88, TIRAP, TRIF, TRAM, NF-κB, IRF3, INF-β, IL-10 and TGF-β genes in follicular cells in both groups are shown in figure 2. MYD88, NF-κB, IL-10, and TGF-β showed a significantly higher expression in endometriosis patients compared to the control ( $p<0.05$ ). The expression of TIRAP, TRIF, TRAM, and IRF3 revealed no significant difference in endometriosis patients compared to the control group. The interferon-β (INF-β) showed significantly lower expression in endometriosis patients compared with the control ( $p<0.05$ ).


The quantitative analysis of IL-6, IL-8, and MIF concentration in FF is shown in figure 3. IL-6, IL-8, and MIF significantly increased in endometriosis cases as compared with the control ( $p<0.05$ ).

## Discussion


Our study was performed to expand our knowledge of the molecular aspects of immune responses in patients with endometriosis. Both anti-inflammatory cytokines, TGF-β and IL-10 and the inflammatory mediators, IL-8, IL-6, MIF, and interferon were investigated as well.

It is hypothesized that dysregulation of immune responses has been involved in the pathophysiology of endometriosis-associated infertility (28). Accordingly, infertile women with endometriosis have a significantly higher expression of TLR1, 5, 6, 7, 8, 10 and significantly lower expression of TLR3, 9 when compared with normal women. However, the expression of TLR2 and 4 was not significantly different between both groups. A significant increase of TLR4 mRNA expression was reported in the ectopic endometriotic lesions compared to corresponding eutopic tissues by Allhorn et al. (29). However, our results indicated that expression of TLR4 in follicular cells of women with endometriosis was not significant compared to the control.

Emerging evidence reported that some of the pro-inflammatory cytokines and chemokines are increasing not only in the endometrium but also in the peritoneal fluid and follicular fluid of women and animals with endometriosis (30-32). Also, many studies have demonstrated pelvic inflammation that is triggered primarily by bacterial endotoxin (Lipopolysaccharide) and is mediated by toll-like receptors and their involvement in the development of pelvic endometriosis has been shown. Our findings suggested that simultaneously with TLR expression in the follicular cells, inflammatory and anti-inflammatory mediators such as IL-8, IL-6, and MIF also increased in follicular fluid. Our findings demonstrate the elevated MIF protein production in these patients which is consistent with previous studies that have shown elevated MIF in peritoneal fluid (33) and peripheral blood of women with endometriosis (34). Increased levels of MIF have adverse effects on capacitation and sperm motility (35). Moreover, MIF binding to CD74 and upregulated IL-8 lead to regulation of inflammatory and immune responses (36, 37). Surprisingly, a significant expression of anti-inflammatory cytokine, TGF-β was seen in follicular cells of women with endometriosis in comparison with control group. It has been reported that, cell adhesiveness, migration, colonization, invasiveness, and development of



**Figure 2.** Q-PCR was used to quantify the expression of MYD88, TIRAP, TRIF, TRAM, NF-κB, IRF3, INF-β, IL-10 and TGF-β genes in granulosa cells in endometriosis and control groups. Data are presented as mean±SEM of normalized expression values against endogenous controls (B-actin and GAPDH mRNA) in POR and control. MYD88, NF-κB, IL-10 and TGF-β showed a significantly higher expression in endometriosis patients compared with the control. The expression of TIRAP, TRIF, TRAM, and IRF3 revealed no significant difference in endometriosis patients compared to the control group. INF-β showed significantly lower expression in endometriosis patients compared with the control group. Data were analyzed by t-test. The level of significance was set at  $p < 0.05$



**Figure 3.** IL-6, IL-8 and MIF protein concentration obtained by ELISA in FF of endometriosis and control groups. IL-6, IL-8, and MIF showed a significantly higher expression in endometriosis cases compared with the control. Data were analyzed by t-test. The level of significance was set at  $p < 0.05$

endometriosis can be increased by high level of TGF-β (38). The interaction between macrophages and endometrial stromal cells (EMSs) may stimulate the secretion of TGF-β and IL-10 that

leads to downregulation of NK cells cytotoxicity and may promote the development of endometrial stripe (EMS) via the immune escape of ectopic fragments (39). Accordingly, a significant increase

of TGF- $\beta$  and IL-10 in FF was detected by immunoassay analysis. Also, TGF- $\beta$  is believed to play a major role in the etiology of peritoneal endometriosis and this may provide an environment favorable to lesion formation (40, 41). The interaction between activated macrophages or maybe follicular cells (TLR stimulation via microbial products leads to macrophages activation) and other stromal cells in women with endometriosis downregulates activation of immune cells, possibly by stimulating the secretion of IL-10 and TGF- $\beta$ , and may further trigger the immune escape of ectopic fragments and promote the occurrence and the development of endometriosis in women (39, 40). TGF- $\beta$  and IL-10 are secreted by many cell types, including macrophages. Inflammatory stimuli (IL-2, IL-10, TGF- $\beta$ ), that activate macrophages and other cells, such as follicular cells enhance the release of active TGF- $\beta$  and IL-10. Moreover, TGF- $\beta$  signalling is a well-studied pathway involved in follicular development and ovulation (42). Generally, our findings disclosed that increased expression of TLRs molecules in follicular cells leads to recruitment and increase of different adaptor molecules such as MyD88, TIRAP, TRAM and TRIF which results in activation of transcription factors including NF-KB and IRFs which in turn induces production of pro-inflammatory cytokines in follicular fluid. Therefore, more detailed investigations are needed to clarify the role of inflammatory or anti-inflammatory responses in the development of endometriosis lesions.

### Conclusion

Our results suggest that the lack of clearance of microbial agents may lead to the identification of pathogen-related structures by TLRs which in turn triggers the adapter and downstream signaling molecules such as NF-KB, MYD-88 and TRIF. As a result, TLRs signaling pathway induces production of inflammatory cytokines and chemokines especially IL-6, IL-8 and MIF in follicular tissues. Increased inflammatory responses and changes in the FF cytokine profile may causes or worsen endometriosis and infertility.

### Acknowledgement

We thank the staff of the female infertility research lab and embryology lab in Royan Institute. This study was conducted with the cooperation of Iran University of Medical Sciences and Royan Institute.

### Conflict of Interest

There are no known conflicts of interest associated with this publication and there has been no significant financial support for this work.

### References

1. Jones R. Bisphenol A and Bisphenol AF potentiate endometriosis differently based on hormonal status in female mice and disrupt normal ovarian function [dissertation]: [USA]: University of Cincinnati; 2018. 54 p.
2. Stilley JAW, Birt JA, Sharpe-Timms KL. Cellular and molecular basis for endometriosis-associated infertility. *Cell Tissue Res*. 2012;349(3):849-62.
3. Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, et al. New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal. *Gynecol Endocrinol*. 2011;27(2):73-9.
4. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril*. 2012;98(3):511-9.
5. Sidell N, Han SW, Parthasarathy S. Regulation and modulation of abnormal immune responses in endometriosis. *Ann N Y Acad Sci*. 2002;955:159-73.
6. Berbic M, Fraser I. Regulatory T cells and other leukocytes in the pathogenesis of endometriosis. *J Reprod Immunol*. 2011;88(2):149-55.
7. Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and immune dysfunction in endometriosis. *Biomed Res Int*. 2015; 2015:795976.
8. Latha M, Vaidya S, Movva S, Chava S, Govindan S, Govatati S, et al. Molecular pathogenesis of endometriosis; Toll-like receptor-4 A896G (D299G) polymorphism: a novel explanation. *Genet Test Mol Biomarkers*. 2011;15(3):181-4.
9. Khan KN, Kitajima M, Fujishita A, Nakashima M, Masuzaki H. Toll-like receptor system and endometriosis. *J Obstet Gynaecol Res*. 2013;39(8):1281-92.
10. Redegeld FA, Yu Y, Kumari S, Charles N, Blank U. Non-IgE mediated mast cell activation. *Immunol Rev*. 2018;282(1):87-113.
11. Amirchaghmaghi E, Taghavi SA, Shapouri F, Saeidi S, Rezaei A, Aflatoonian R. The role of toll like receptors in Pregnancy. *Int J Fertil Steril*. 2013;7(3):147-54.
12. McKernan DP. Toll-like receptors and immune cell crosstalk in the intestinal epithelium. *AIMS Allergy Immunol*. 2019;3(1):13.
13. Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol*. 2003;21:335-76.

14. Jafari R, Aflatoonian R, Falak R, Pourmand G, Dehghani S, Mortazavi M, et al. Down-regulation of inflammatory signaling pathways despite up-regulation of Toll-like receptors; the effects of corticosteroid therapy in brain-dead kidney donors, a double-blind, randomized, controlled trial. *Mol Immunol*. 2018;94:36-44.
15. Kawai T, Akira S. TLR signaling. *Semin Immunol*. 2007;19(1):24-32.
16. Fazeli A, Bruce C, Anumba DO. Characterization of Toll-like receptors in the female reproductive tract in humans. *Hum Reprod*. 2005;20(5):1372-8.
17. Aflatoonian R, Tuckerman E, Elliott SL, Bruce C, Aflatoonian A, Li TC, et al. Menstrual cycle-dependent changes of Toll-like receptors in endometrium. *Hum Reprod*. 2007;22(2):586-93.
18. Aboussahoud W, Aflatoonian R, Bruce C, Elliott S, Ward J, Newton S, et al. Expression and function of Toll-like receptors in human endometrial epithelial cell lines. *J Reprod Immunol*. 2010;84(1):41-51.
19. Taghavi SA, Ashrafi M, Mehdizadeh M, Karimian L, Joghataie MT, Aflatoonian R. Toll-like receptors expression in follicular cells of patients with poor ovarian response. *Int J Fertil Steril*. 2013;8(2):183-92.
20. Gholamnezhadjafari R, Tajik N, Falak R, Aflatoonian R, Dehghan S, Rezaei A. Innate inflammatory gene expression profiling in potential brain-dead donors: detailed investigation of the effect of common corticosteroid therapy. *Innate Immun*. 2017;23(5):440-8.
21. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is endometriosis associated with systemic subclinical inflammation? *Gynecol Obstet Invest*. 2006;62(3):139-47.
22. Zarmakoupis PN, Rier SE, Maroulis GB, Becker JL. Uterus and endometrium: inhibition of human endometrial stromal cell proliferation by interleukin 6. *Hum Reprod*. 1995;10(9):2395-9.
23. Rier SE, Zarmakoupis PN, Hu X, Becker JL. Dysregulation of interleukin-6 responses in ectopic endometrial stromal cells: correlation with decreased soluble receptor levels in peritoneal fluid of women with endometriosis. *J Clin Endocrinol Metabol*. 1995;80(4):1431-7.
24. [No authors listed]. Revised American society for reproductive medicine classification of endometriosis: 1996. *Fertil Steril*. 1997;67(5):817-21.
25. Rezazadeh Valojerdi M, Eftekhari-Yazd P, Karimian L, Hassani F, Movaghar B. Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. *J Assist Reprod Genet*. 2009;26(6):347-54.
26. Mönkkönen KS, Aflatoonian R, Lee KF, Yeung WS, Tsao SW, Laitinen JT, et al. Localization and variable expression of G alpha(i2) in human endometrium and fallopian tubes. *Hum Reprod*. 2007;22(5):1224-30.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25(4):402-8.
28. Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? *Clin Chim Acta*. 2019;493:63-72.
29. Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw I. TLR3 and TLR4 expression in healthy and diseased human endometrium. *Reprod Biol Endocrinol*. 2008;6:40.
30. Kyama CM, Overbergh L, Mihalyi A, Meuleman C, Mwenda JM, Mathieu C, et al. Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis. *Fertil Steril*. 2008;89(2):301-10.
31. Xu H, Schultze-Mosgau A, Agic A, Diedrich K, Taylor RN, Hornung D. Regulated upon activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein 1 in follicular fluid accumulate differentially in patients with and without endometriosis undergoing in vitro fertilization. *Fertil Steril*. 2006;86(6):1616-20.
32. Bedaiwy M, Shahin AY, AbulHassan AM, Goldberg JM, Sharma RK, Agarwal A, et al. Differential expression of follicular fluid cytokines: relationship to subsequent pregnancy in IVF cycles. *Reprod Biomed Online*. 2007;15(3):321-5.
33. Kats R, Collette T, Metz CN, Akoum A. Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. *Fertil Steril*. 2002;78(1):69-76.
34. Morin M, Bellehumeur C, Therriault MJ, Metz C, Maheux R, Akoum A. Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. *Fertil Steril*. 2005;83(4):865-72.
35. Carli C, Leclerc P, Metz CN, Akoum A. Direct effect of macrophage migration inhibitory factor on sperm function: possible involvement in endometriosis-associated infertility. *Fertil Steril*. 2007;88(4 Suppl):1240-7.
36. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast

- cancer. *Cancer Lett.* 2008;261(2):147-57.
37. Beswick EJ, Reyes VE. Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during *Helicobacter pylori* exposure induce expression and activation of the epidermal growth factor receptor. *Infect Immun.* 2008;76(7):3233-40.
  38. Soni UK, Chadchan SB, Kumar V, Ubba V, Khan MTA, Vinod BSV, et al. A high level of TGF-B1 promotes endometriosis development via cell migration, adhesiveness, colonization, and invasiveness. *Biol Reprod.* 2018;100(4):917-38.
  39. Yang HL, Zhou WJ, Chang KK, Mei J, Huang LQ, Wang MY, et al. The crosstalk between endometrial stromal cells and macrophages impairs cytotoxicity of NK cells in endometriosis by secreting IL-10 and TGF- $\beta$ . *Reproduction.* 2017;154(6):815-25.
  40. Young VJ, Brown JK, Saunders PT, Duncan WC, Horne AW. The peritoneum is both a source and target of TGF- $\beta$  in women with endometriosis. *PloS one.* 2014;9(9):e106773.
  41. Young VJ, Ahmad S, Duncan WC, Horne AW. The role of TGF- $\beta$  in the pathophysiology of peritoneal endometriosis. *Hum Reprod Update.* 2017;23(5):548-59.
  42. da Silveira JC, Winger QA, Bouma GJ, Carnevale EM. Effects of age on follicular fluid exosomal microRNAs and granulosa cell transforming growth factor- $\beta$  signalling during follicle development in the mare. *Reprod Fertil Dev.* 2015;27(6):897-905.